SCHEMBL26019486

SCHEMBL26019486

CC(C)OC(=O)[C@H](C)CCOP1(=O)OC[C@H]2O[C@@H](n3ccc(N)nc3=O)C(F)(F)C2O1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PDE3A Q14432 3/20 0.43
▸ PDE4D Q08499 1/20 0.43
▸ SLC29A1 Q99808 1/20 0.43
▸ POLA1 P09884 2/20 0.40
▸ STING1 Q86WV6 6/20 0.35
▸ POLG P54098 2/20 0.34
▸ LMNA P02545 3/20 0.33
▸ CACNA1F O60840 2/20 0.33
▸ ALB P02768 2/20 0.33
▸ MAPT P10636 2/20 0.33
▸ CACNA1D Q01668 2/20 0.33
▸ CACNA1S Q13698 2/20 0.33
▸ CACNA1C Q13936 2/20 0.33
▸ THRB P10828 1/20 0.32
▸ MTOR P42345 1/20 0.32
▸ MDM2 Q00987 1/20 0.32
▸ NCOA1 Q15788 1/20 0.32
▸ NCOA3 Q9Y6Q9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20221839 1.00 PDE3A (0.43) PDE3APDE4DSLC29A1POLA1STING1
SCHEMBL20221837 1.00 PDE3A (0.43) PDE3APDE4DSLC29A1POLA1STING1
SCHEMBL18270574 1.00 PDE3A (0.43) PDE3APDE4DSLC29A1POLA1STING1
SCHEMBL18270569 1.00 PDE3A (0.43) PDE3APDE4DSLC29A1POLA1STING1
SCHEMBL18270575 1.00 PDE3A (0.43) PDE3APDE4DSLC29A1POLA1STING1
SCHEMBL18270570 1.00 PDE3A (0.43) PDE3APDE4DSLC29A1POLA1STING1
SCHEMBL18270536 0.93 PDE3A (0.43) PDE3APDE4DSLC29A1POLA1STING1
SCHEMBL18270573 0.93 PDE3A (0.43) PDE3APDE4DSLC29A1POLA1STING1
SCHEMBL20221830 0.93 PDE3A (0.43) PDE3APDE4DSLC29A1POLA1STING1
SCHEMBL21107690 0.93 PDE3A (0.43) PDE3APDE4DSLC29A1POLA1STING1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11730748-B2 Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases MSD INTERNATIONAL GMBH (CH) 2023-08-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11730748-B2 Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases SLC10A1, PNP, PYGL PDE3A 319/4885PDE4D 266/4885SLC29A1 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback